-+ 0.00%
-+ 0.00%
-+ 0.00%

Kyverna Therapeutics FY2025 net loss widens 27% to $(161) million; interest expense jumps 244% to $(489,000)

Reuters·03/26/2026 20:12:27

Please log in to view news